InMed Pharmaceuticals Inc INM

Healthcare Cannabis

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.

NDAQ:INM - Post by User

InMed Pharmaceuticals Inc > Adams' Options

<< Previous

Bullboard Posts

Next >>

Post by Steveminon Apr 16, 2021 3:57pm

201 Views

Post# 33012828

Adams' Options

Adams has about 60k options (at an exercise price of $2.02 US) that are expiring next month (5/15). Will be very interesting to see if he exercises any of them. At that cheap of a price, if he chooses NOT to exercise any of them, then I'd say there is a sh&t ton of trouble on the ol' Inmed homefront.

Either way, he's got to go. Now.

<< Previous

Bullboard Posts

Next >>

NTG Clarity Networks' growth story continues with $22M contract